Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial

Blood

Volumn 101, Issue 7, 2003, Pages 2563-2569

  Muul, Linda Mesler ^a   Tuschong, Laura M ^b   Soenen, Sherry Lau ^b   Jagadeesh, G Jayashree ^b   Ramsey, W Jay ^b   Long, Zhifeng ^b   Carter, Charles S ^b   Garabedian, Elizabeth K ^b   Alleyne, Melinna ^b   Brown, Margaret ^b   Bernstein, Wendy ^b   Schurman, Shepherd H ^b   Fleisher, Thomas A ^b   Leitman, Susan F ^b   Dunbar, Cynthia E ^b   Blaese, R Michael ^b   Candotti, Fabio ^b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; COMPLEMENTARY DNA; MACROGOL; OKT 3; RECOMBINANT ENZYME; RETROVIRUS VECTOR; VIRUS ANTIBODY; HETEROPHILE ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; PEGADEMASE BOVINE;

ARTICLE; CASE REPORT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME DEFICIENCY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE TRANSFER; HUMAN; INFUSION; LONG TERM CARE; LONG TERMINAL REPEAT; LONGEVITY; LYMPHOCYTE; MOLONEY LEUKEMIA ONCOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS RECOMBINANT; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BLOOD; CATTLE; CYTOLOGY; DISORDERS OF PURINE AND PYRIMIDINE METABOLISM; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; METABOLISM; METHODOLOGY;

ADENOSINE DEAMINASE; ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CATTLE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LONGITUDINAL STUDIES; MOLONEY MURINE LEUKEMIA VIRUS; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0038446699     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2800     Document Type: Article

References (31)

1. Hirschhorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press; 1999:121-139.
2. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency ciency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:2585-2625.
3. Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91:3646-3653.
4. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508-516.
5. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589-596.
6. Valentine WN, Paglia DE. Erythrocyte disorders of purine and pyrimidine metabolism. Hemoglobin. 1980;4:669-681.
7. Culver KW, Anderson WF, Blaese RM. Lymphocyte gene therapy. Hum Gene Ther. 1991;2:107-109.
8. Hock RA, Miller AD, Osborne WR. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood. 1989;74:876-881.
9. Blaese RM, Culver, KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270:475-480.
10. Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum Gene Ther. 1996;7:1123-1129.
11. Kohn DB, Kantoff PW, Eglitis MA, et al. Retroviral-mediated gene transfer into mammalian cells. Blood Cells. 1987;13:285-298.
12. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 1995;4:357-362.
13. Wada T, Schurman SH, Otsu M, et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A. 2001;98:8697-8702.
14. Kohn DB, Mitsuya H, Ballow M, et al. Establishment and characterization of adenosine deaminase-deficient human T cell lines. J Immunol. 1989;142:3971-3977.
15. Cornetta K, Moen RC, Culver K, et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1990;1:15-30.
16. + selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Hum Gene Ther. 1993;4:521-527.
17. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy." J Exp Med. 1994;179:609-618.
18. + T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Mol Med. 1995;1:614-624.
19. + T cell expansions in normal individuals and patients with rheumatoid arthritis. J Immunol. 1995;154:3538-3547.
20. Gorski J, Yassai M, Zhu X, et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping: correlation with immune status. J Immunol. 1994;152:5109-5119.
21. Nolta JA, Dao MA, Wells S, Smogorzewska EM, Kohn DB. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc Natl Acad Sci U S A. 1996;93:2414-2419.
22. Szatalowicz FT, Blenden DC, Parker CL. Micromodification of the Ouchterlony gel diffusion precipitin technique. Am J Vet Res. 1969;30:149-150.
23. Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 1998;91:30-36.
24. Cornetta K, Morgan RA, Gillio A, et al. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum Gene Ther. 1991;2:215-219.
25. Long Z, Li LP, Grooms T, et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther. 1998;9:1165-1172.
26. Levy Y, Hershfield MS, Fernandez-Mejia C, et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr. 1988;113:312-317.
27. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood. 1997;89:776-779.
28. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
29. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
30. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 1995;270:470-475.
31. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning. Science. 2002;296:2410-2413.